- Home
- FTFT vs CANF Comparison
FTFT vs CANF Comparison
Compare FTFT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- CANF
- Stock Information
- Founded
- FTFT N/A
- CANF 1994
- Country
- FTFT United States
- CANF Israel
- Employees
- FTFT 40
- CANF N/A
- Industry
- FTFT Business Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- CANF Health Care
- Exchange
- FTFT Nasdaq
- CANF Nasdaq
- Market Cap
- FTFT 11.0M
- CANF 9.6M
- IPO Year
- FTFT N/A
- CANF N/A
- Fundamental
- Price
- FTFT $3.18
- CANF $0.67
- Analyst Decision
- FTFT
- CANF Strong Buy
- Analyst Count
- FTFT 0
- CANF 2
- Target Price
- FTFT N/A
- CANF $14.50
- AVG Volume (30 Days)
- FTFT 281.4K
- CANF 135.8K
- Earning Date
- FTFT 08-19-2025
- CANF 08-26-2025
- Dividend Yield
- FTFT N/A
- CANF N/A
- EPS Growth
- FTFT N/A
- CANF N/A
- EPS
- FTFT N/A
- CANF N/A
- Revenue
- FTFT $2,368,206.00
- CANF $560,000.00
- Revenue This Year
- FTFT N/A
- CANF $461.72
- Revenue Next Year
- FTFT N/A
- CANF N/A
- P/E Ratio
- FTFT N/A
- CANF N/A
- Revenue Growth
- FTFT N/A
- CANF N/A
- 52 Week Low
- FTFT $1.01
- CANF $0.63
- 52 Week High
- FTFT $5.70
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- FTFT 74.35
- CANF 41.47
- Support Level
- FTFT $2.00
- CANF $0.64
- Resistance Level
- FTFT $3.10
- CANF $0.68
- Average True Range (ATR)
- FTFT 0.36
- CANF 0.02
- MACD
- FTFT 0.09
- CANF 0.01
- Stochastic Oscillator
- FTFT 63.16
- CANF 91.25
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).